Revolution Medicines director plans 15,080-share sale

A Revolution Medicines director filed a Rule 144 notice to sell 15,080 option shares of common stock over roughly three months.

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) director Elizabeth Anderson filed a notice of proposed sale of company common stock under Rule 144. The notice covers up to 15,080 shares to be sold through Morgan Stanley Smith Barney LLC, with an approximate aggregate market value of $2,906,820.80 and a stated sale date of September 22, 2026 on NASDAQ. The shares are to be acquired from the issuer by cash exercise of stock options, and the remark states that the securities were and will be received upon option exercises and sold over the next three months. The filing also reports that 214,336,418 shares of common stock were outstanding.

Key Figures

Shares proposed for sale: 15,080 shares Aggregate market value of securities to be sold: $2,906,820.80 Shares outstanding: 214,336,418 shares +1 more

4 metrics

Shares proposed for sale 15,080 shares Common stock covered by the Rule 144 notice

Aggregate market value of securities to be sold $2,906,820.80 Approximate market value of the 15,080 shares in the notice

Shares outstanding 214,336,418 shares Common stock outstanding as reported in the Form 144

Planned sale date September 22, 2026 Stated date for the proposed sale of common stock

Key Terms

Rule 144, Exercise of Stock Options, aggregate market value, NASDAQ

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Exercise of Stock Options financial

"Common | 09/22/2026 | Exercise of Stock Options | Issuer"

aggregate market value financial

"15080 | 2906820.80 | 214336418 | 09/22/2026 | NASDAQ"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

NASDAQ market

"214336418 | 09/22/2026 | NASDAQ"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for RVMD disclose about Elizabeth Anderson's planned sale?

The Form 144 discloses that director Elizabeth Anderson plans to sell up to 15,080 shares of Revolution Medicines common stock, to be acquired by exercising stock options for cash and sold over approximately the next three months, with a stated sale date of September 22, 2026.

How many RVMD shares does the Rule 144 notice cover and what is their value?

The notice covers 15,080 shares of Revolution Medicines common stock with an approximate aggregate market value of $2,906,820.80. This figure reflects the total market value of the securities indicated for potential sale in the filing.

How will Elizabeth Anderson acquire the RVMD shares she plans to sell?

Elizabeth Anderson will receive the shares upon the exercise of stock options. The filing states that the securities to be sold were and will be received upon the exercise of stock options from the issuer, with cash as the nature of payment.

Over what period does the RVMD Form 144 say the option exercises and sales will occur?

The remarks state that the securities to be sold were and will be received upon the exercise of stock options over the next three months, and that the dates of acquisition and payment were and will be the dates of exercise and sale.

How many Revolution Medicines (RVMD) shares were outstanding as reported in this notice?

The Form 144 reports that 214,336,418 shares of Revolution Medicines common stock were outstanding. This figure provides context for the scale of the 15,080-share proposed sale under Rule 144.

Which broker is handling the planned RVMD stock sale under Rule 144?

The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza in New York, as the broker for the proposed sale of 15,080 shares of Revolution Medicines common stock on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/22/2026 - 04:13 PM Accepted by SEC EDGAR 09/22/2026 - 04:13 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001758247
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	REVOLUTION MEDICINES INC
SEC File Number	001-39219
Address of Issuer	700 Saginaw Drive Redwood City CALIFORNIA 94063
Phone	6504816801
Name of Person for Whose Account the Securities are To Be Sold	Elizabeth Anderson
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	15080	2906820.80	214336418	09/22/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/22/2026	Exercise of Stock Options	Issuer			15080	09/22/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Date of Notice	09/22/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/23/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Elizabeth Anderson
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)